| Name | Title | Contact Details |
|---|
Hartford HealthCare is Connecticut`s most comprehensive healthcare network. With 33,000 employees and total operating revenue of $4.3 billion, Hartford HealthCare has cultivated a strong, unified culture of accountability and innovation. Its care-delivery system, serving 185 towns and cities at more than 400 locations, includes two tertiary-level teaching hospitals, an acute-care community teaching hospital, an acute-care hospital and trauma center, three community hospitals, the state`s most extensive behavioral health network, a large multispecialty physician group, a clinical care organization, a regional home care system, an array of senior care services, and a large physical therapy and rehabilitation network. Hartford HealthCare`s unique, systemwide Institute Model offers a single, high standard of care in crucial specialties at hospital and ambulatory sites across Connecticut. The institutes include: Cancer, Heart and Vascular, Neuroscience, Orthopedics and Urology.
Fulton Co. Emergency Medical Association is a Canton, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Institute for Family Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The Institute for Family Health is based in New York, NY. You can find more information on The Institute for Family Health at www.institute2000.org
MEDWRITE Medical Communications is a Maiden Rock, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.